从崩到突破:免疫蛋白酶可以彻底改变免疫疗法
Cody A Loy1, Darci J Trader1,2,3
1Department of Pharmaceutical Sciences, University of California, Irvine, California 92617, United States.
Journal of medicinal chemistry
|October 13, 2025
概括
免疫反应的关键参与者免疫蛋白酶 (iCP) 是新疗法的一个有希望的目标. 了解iCP的理解 iCP的理解
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 免疫蛋白酶体 (iCP) 是一种专门的蛋白质酶体异型体.
- iCP在患病细胞中升级调节,对于产生MHC-I来说至关重要.
- iCP是癌症,自身免疫疾病和炎症治疗的有吸引力的目标.
研究的目的:
- 探索当前的免疫疗法策略.
- 调查ICP作为治疗疗效的生物标志物的作用.
- 为了开发新型免疫疗法,利用iCP.
主要方法:
- 关于免疫治疗策略的文献综述.
- 分析iCP在生成中的作用.
- 探索iCP在治疗开发中的潜力.
主要成果:
- iCP在MHC-I生成中发挥着重要作用.
- iCP可以作为免疫疗法疗效的指标.
- iCP为新型治疗策略提供了潜力.
结论:
- 免疫蛋白酶体是一个快速出现的药物点.
- 利用ICP可以改善癌症,自身免疫和炎症治疗.
- iCP 具有显著的免疫疗法进步潜力.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome
10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
The Proteasome
4.4K
4.4K
The Proteasome Structure
1.6K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.6K
Proteomics
9.3K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.3K


